

Rec'd PCT/PTO 28 JUN 2004

PCT/EP 02 / 14315



INVESTOR IN PEOPLE

Rec'd PCT/PTO 28 JUN 2004

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

10/500431

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 27 JAN 2003

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., P.L.C. or PLC.

Registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*R. Mahoney*

Dated 2 January 2003

BEST AVAILABLE COPY


## Patents Form 1/77

Patents Act 1977  
(Rule 16)

PCT/E 2 / 1 4 3 1 5

28DEC01 E684618-1 D03022  
001/7700 0.00-0131014.3**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference PL0197

2. Patent application number  
(The Patent Office will fill in this part)

0131014.3

28 DEC 2001

3. Full name, address and postcode of the or of each applicant (underline all surnames)

JAMES, Peter  
Villan  
Solvegatan 2  
223 62 Lund  
Sweden

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

08225773001

4. Title of the invention

METHOD FOR MOLECULE-MOLECULE ANALYSIS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

HAMMER, Catriona, MacLeod; ROLLINS, Anthony, John and HAMMETT, Audrey, Grace, Campbell  
Amersham plc  
The Grove Centre  
White Lion Road  
Amersham  
Buckinghamshire HP7 9LL  
United Kingdom

079 33013003

Patents ADP number (if you know it)

08225773002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

NO

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

0025104 28-Dec-01 02:14

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

## Continuation sheets of this form

Description 18 ✓  
Claim(s) 3 ✓  
Abstract 1 ✓  
Drawing(s) 6 only

10. If you are also filing any of the following, state how many against each item.

## Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) 1 ✓

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

HAMMER, Catriona, MacLeod

Signature

Date  
28 December 2001

12. Name and daytime telephone number of person to contact in the United Kingdom HALLS, Jennie 01494 545064

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.  
b) Write your answers in capital letters using black ink or you may type them.  
c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.  
d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.  
e) Once you have filled in the form you must remember to sign and date it.  
f) For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

0025104-28-Dec-01 02:14

DUPLICATE

1

METHOD FOR MOLECULE-MOLECULE INTERACTION ANALYSISTechnical field

- 5 The invention relates to a method for labelling and analysing molecule-molecule interactions by mass spectroscopy. Furthermore, the invention relates to a specific linker molecule and a kit for use in the method.

Background

- 10 The success of the genome projects (up to the end of December 2000, over 150 prokaryotic and 40 eukaryotic genomes are in progress or have been completed) has resulted in the identification of a vast number of open reading frames which potentially code for proteins. The main problem is now to assign functions to the forty to sixty percent of the ORFs in a genome for which no function can be allocated. Two
- 15 analytical chemical approaches to this can be identified: transcriptomics and proteomics. Transcriptomics analyses the expression levels of the various mRNA species being transcribed using either a 'gene-chip' or a SAGE approach. This is useful for identifying under which conditions a particular protein is being expressed but provides little direct information as to function. Proteomics, the direct quantitation
- 20 and analysis of expressed proteins, provides a more direct approach to function definition. Proteomics can be divided into two areas: Expression Proteomics attempts to define all the proteins being expressed in a cell and their post-translational modifications and how these change under various conditions. Cell-Map Proteomics attempts to define the subcellular location of a protein and with which other
- 25 proteins it is interacting. It is this field which the inventors wish to address in this grant application.

- Traditionally, protein-protein interactions have been analysed by the isolation of protein complexes by 'soft' non-denaturing physico-chemical methods such as cen-
- 30 trifugation or affinity based isolations. This approach has been facilitated by the use

of mass spectrometry to analyse the purified protein complexes either as mixtures or after separation by SDS-PAGE. The method suffers from several drawbacks, the main one being the stability of the complex under the conditions of purification and a lack of a general purification approach to allow a systematic analysis of many proteins. The latter problem has been successfully addressed by the development of the TAP procedure by the group of Bernard Seraphin at EMBL (Rigant et al., Nat Biotechnol 1999 Oct; 17(10): 1030-2 and Puig et al., Methods 2001 Jul; 24(3): 218-29). ORFs are modified so that the proteins they encode contain two affinity purification (TAP) tags, which allow the labelled protein to be rapidly purified to homogeneity. The resulting complex is then analysed by mass spectrometry to identify the co-purifying proteins.

An alternative approach to protein-protein interaction analysis has been the development of the yeast and bacterial two- and three-hybrid systems (Fromont-Racine et al., Nat Genet 1997 Jul; 16(3): 277-82 and Uetz et al., Nature 2000 Feb 10; 403(6770): 623-7). This has allowed genome-wide scans of all protein-protein interactions in a genome to be carried out. The main drawback here is that transient interactions and those induced by ligands or phosphorylation are not amenable to analysis by this method. The TAP purification and two-hybrid system methods do not allow one to define which protein is interacting with which other protein in the complex and which parts of the two proteins are involved in this interaction.

Accordingly, there is a need for a new method in the field of proteomics, solving the posed problems, thereby providing a more detailed information about molecule-molecule interactions.

#### Summary of the invention

One object of the invention is to provide a method meeting the demands on this point. This and other objects are accomplished by a method for labelling a target biomolecule, interacting with a specific biomolecule of interest (or bait) as disclosed

in the first claim of the application. Hereby, the target biomolecule is labelled with a unique mass marker, which preferably is detected by mass spectroscopy, using a parent ion scanning mode. The method is of a rather general applicability, allowing the studying of interactions between several types of biomolecules. However, the study of interactions between proteins and small molecules or ligands is at focus. Furthermore, the invention relates to a linker molecule for use in labelling the specific target and a kit for use in the method of the invention.

An advantage with the present invention is that it enables focus on transient and low affinity protein-protein (ligand) interactions that the conventional methods described in the introduction do not allow. The inventors disclose herein a mass spectrometric approach that will enable one to pick out the 'target protein' to which the labelled 'bait protein' has been crosslinked. The protein of interest, the 'bait' is modified with a chemical or photoactivatable linker either 'in situ' or externally and then introduced into the cells. The bait can then be cross-linked by photolysis to the target under defined conditions. The cell is then lysed and the crosslinker cleaved to leave a unique chemical label (the mass marker) on the target, which allows it to be rapidly identified by 'parent ion' scanning in a mass spectrometer. The method 'mass marker transfer' is applicable not only to protein-protein interaction mapping but also to determining the targets of small organic (or inorganic) molecules (ligands) in the cell. This approach has the advantage in that it not only enables one to identify the interacting partner but also to determine the domain on the protein responsible for the interaction. The method is ideally suited to the analysis of rapid transient interactions such as those that occur in signalling cascades as well as for the identification of receptors for small molecules such as drugs or signalling metabolites.

#### Brief description of the drawings

Figure 1 shows the general form of linker molecule of the invention.

Figure 2 shows the chemical structure of a specific linker of the invention.

Figure 3 is a schematic outline of the principle of the mass marker transfer method of the invention.

Figure 4 shows the parent ion scanning principle.

Figure 5 shows a daughter ion spectrum and HPLC UV vs. RIC trace.

5 Figure 6 is a photo of a diagonal gel electrophoresis run.

### Definitions

By "a target biomolecule" is in this context meant the molecule which is desired to find and analyse.

10 By the term "interacting biomolecule" is meant a biomolecule that can attach to a target by chemical binding, ionic interaction, hydrogen bonding, affinity adsorption or any other principle that couple one biomolecule to another. The interaction may well be based on more than one of the above mentioned principles.

By "a biomolecule of interest", or "bait" is meant a molecule potentially having  
15 specificity for the target biomolecule. It is the interaction between the biomolecule of interest and the target biomolecule that is desired to monitor by the invention.

By "linker molecule" is meant a molecule, which is used for cross-linking the biomolecule of interest and the target biomolecule. The linker molecule comprises "an attachment part" for binding to the biomolecule of interest, "a photoactivatable  
20 part", which has the ability to be activated and thereby be able to bind to the target biomolecule, "a cleavable part", which may be cleaved during the analysis step of the invention, and "a mass marker part" which provides a unique mass marker for the subsequent analysis.

### 25 Detailed description of the invention

A first aspect of the invention is a method for identifying an interacting target biomolecule to a biomolecule of interest comprising the steps of:

- (a) providing a biomolecule of interest having specificity for the target;
- (b) binding the biomolecule of interest to at least one type of linker molecule, the  
30 linker molecule comprising at least one attachment part for binding to the

biomolecule of interest, one cleavable part, one mass marker part and one photoactivatable part, for binding to the target;

- (c) contacting the biomolecule of interest with a cell or a cell extract;
- (d) exposing the cell to photolysis, whereby the photoactivatable part binds to the target;
- (e) cleaving the linker molecule, thereby leaving the photoactivatable part and the mass marker part bound to the target;
- (f) analysing the product of step (e), thereby detecting the mass marker part, thus identifying the interacting target biomolecule to the biomolecule of interest.

The target biomolecule is a polypeptide, a protein, a nucleotide, a small molecule, or any other biomolecule, such as a fatty acid or a carbohydrate. Preferably, the target biomolecule is a protein.

As a first step of the invention the biomolecule of interest is provided. Preferably, the biomolecule of interest is provided in a concentration as close as possible to that as is naturally found in the cell type being analysed. The method for isolating the biomolecule of interest depends on the nature of the molecule. For instance, drug molecules may be provided by chemical synthesis, and proteins by expression and purification. The biomolecule of interest is any biomolecule, small molecule or ligand, which potential interaction with another biomolecule is desired to study. Accordingly, if its interaction with a specific target is already known, the present method can be used to determine whether such a target is present in a specific cell. This can for example be used in diagnosis of disease, where the target then is a known marker of a disease condition. Alternatively, various ligands, such as a combinatorial library of peptides, may be tested for their ability to bind specific target known to be present in a cell. This can for example be used in the screening of new drugs or drug candidates. In one embodiment the biomolecule of interest is selected from the group that consists of a polypeptide, a protein, a nucleotide, a small organic or inorganic molecule, a fatty acid and a carbohydrate. Preferably, the biomolecule



of interest is a peptide, or a small molecule. In this context, the term "small" is used for molecules sufficiently small for the herein described use. The minimum size of the biomolecule of interest is what is required for efficient binding. For instance, this may be tried out using a series of different sizes, whereby the best is chosen.

5 The affinity of the biomolecule of interest for the target biomolecule should be sufficiently strong for the binding to last long enough for the herein disclosed purpose, i.e. to enable an identification of a target, and may for example be in the mM to pM range, for example 10 mM to 0.1pM.

10 Thereafter (step b), the biomolecule of interest is bound, preferably by photoactivation under conditions as close to native as possible, to a linker molecule. The linker molecule comprises an attachment part for binding to the biomolecule of interest. In one embodiment, the attachment part of the linker molecule is designed to bind a specific amino acid residue of the biomolecule of interest. In a preferred embodi-  
15 ment, the attachment part is a N-hydroxysuccinimide moiety or a N-maleimide.

Furthermore, the linker molecule comprises a photoactivatable part, for subsequent binding to a target biomolecule, a mass-marker part, for allowing analysis of the target, and a cleavable part, for separation of the target and the agent.

20

In the next step (step c), the biomolecule of interest is introduced in a cell either by active uptake (usually cells pick up peptides naturally by pinocytosis) or by permeabilising the cells temporarily, e.g. by digitonin. Alternatively, a cell free system may be used, especially if one or more of the present biomolecules are carbohy-  
25 drates. Also, the cell may be perforated or in the form of a cell extract. The mixture obtained of biomolecule of interest and cell or cell extract is the allowed a sufficient period of time for the desired binding to occur. In one embodiment where the target biomolecule is a nucleotide, the method also either provides entrance thereof into a nucleus of a cell or alternatively the interacting biomolecule is contacted with a dis-  
30 rupted nucleus.

Alternatively, the experiment may be carried out in cell extracts.

5 Thereafter, the cell or the cell-free system is exposed to photolysis. The system is preferably kept at constant temperature, and any standard UV lamp is useable. Preferably, a tungsten carbide lamp is favoured after filtering to remove far UV, which is done by passing the light through a 1M copper sulphate solution (path length 1 cm). Hereby, the photoactivatable part of the linker molecule is activated, thereby allowing it to bind to the target biomolecule. In one embodiment, the photoacti-  
10 vatable part is an azide or a benzophenone. Benzophenone may need repeated photoactivations in order to bind to the target. However, if repeated activations are performed, the probability for the benzophenone-part to bind to the target may be as high as 80 %.

15 If the activatable part is a compound that can be activated by chemical means, the activation is provided by adding such a suitable chemical. Chemical activation is well known in the field of biochemistry, and the skilled person can easily choose a suitable combination of chemically activatable part/chemical degrador or cleaver.

20 The advantage of activating the above discussed part for binding after it has entered the cell is that undesired unspecific binding with other molecules is then avoided. However, the above discussed part may have been activated to be able to bind a target before being contacted with the cell, as long as the binding to the target is sufficiently specific for the method to be functional.

25 Furthermore, in order to achieve an adequate degree of binding, i.e. one that lasts throughout the present procedure and one that can withstand the conditions used (normally about 10% binding degree is necessary), target linker molecules having varying lengths may be used in the invention, in order to secure that at least some of  
30 the linkers bind to the target. Moreover, if the linker molecule is (very) long, it may

tend to bind water, thereby limiting its activity for the target. The reason for the linker molecule to be used in varying lengths, is that due to the nature of the method, the site where the linker molecule may bind to the target as well as the parts of the biomolecule of interest and the target biomolecule that interact to one another, are unknown at forehand. Thus, it is desired to provide a linker molecule, which has the ability to bind to the target biomolecule, even though there might be some distance between the binding site to the biomolecule of interest and to the target biomolecule. Moreover, by using linker molecules having varying lengths, information about the naturally occurring interaction between the bait and the target may be provided; i.e. by studying what length of the linker molecule is optimal for binding to the target, information about distances between interacting parts of the target and the bait may be revealed.

As mentioned above, in a specific embodiment, the present biomolecules are nucleotides, in which case the above described linker is tailored to link a nucleotide to another nucleotide, while keeping the feature of being cleavable as described above. Similarly, in alternative embodiments, the biomolecules are carbohydrates, and the linker can link a carbohydrate to another carbohydrate. Especially advantageous embodiments are when the biomolecules i.e. the target and the biomolecule of interest are of different kinds, in which cases the linker is capable of providing e.g. nucleotide-protein crosslinking, protein-carbohydrate etc..

Subsequently (step (e)), the linker molecule is cleaved, thereby releasing the biomolecule of interest from the target biomolecule, and leaving the part of the linker molecule comprising the mass marker bound to the target. The cleaving of the cleavable part of the linker molecule may be performed by chemical means. In one embodiment the cleavable part is cleaved by an oxidising agent or by a base agent. More specifically, the cleavable part may be a geminal diol or an ester linkage, which can be cleaved by mild oxidation with 10 mM periodate (30 minutes, room

temperature) or basic conditions (> pH 9 for two hours, room temperature), respectively.

Optionally, the product of step (e) of the invention, the target biomolecule, may be  
5 cleaved by enzymatic means either separately or combined with the above discussed  
chemical means. For instance, the digestion may be performed by using cyanogen  
bromide and/or trypsin. The cleaving can comprise an enzymatic digestion, such as  
with an enzyme, such as a protease (e.g. trypsin, V8 protease, such as *Staphylococcus*  
10 *aureus* V8 protease, LysC, AspN etc) or a glycosidase, or a chemical digestion,  
such as with cyanogen bromide. However, as regards membrane and/or membrane  
associated proteins, due to their compact structure and tendency to aggregate when  
denatured, conventional enzyme digestions can be found to be inefficient. In one  
embodiment which is especially advantageous for membrane and/or membrane  
15 proteins, the cleaving in step (b) is an enzymatic digestion preceded by addition of a  
digestive chemical, such as cyanogen bromide. More specifically, the present in-  
ventors have used a scheme wherein the proteins are first digested with cyanogen  
bromide in a powerful solvent, such as 70% formic or trifluoroacetic acid, with or  
without hexafluoropropanol. This generates medium sized fragments which can be  
20 readily solubilised by a conventional method, e.g. in 1% SDS, before dilution to  
about 0.01% and digestion with LysC protease. In an alternative embodiment, acid-  
based cleavages are used, as reported by the group of Tsugita (Kamo et al. 1998 and  
Kawakami et al. 1997). Thus, in one embodiment, the cleaving in step (b) is a ser-  
ine/threonine cleavage with a fluorinated acid. In a detailed embodiment, site spe-  
25 cific cleavage at serine and threonine is carried out in peptides and proteins with S-  
ethyltrifluorothioacetate vapour as well as at aspartic acid residues by exposure to  
0.2% heptafluorobutyric acid vapour at 90°C. Such a serine/threonine cleavage  
method is advantageous, since Ser and especially Thr are found often in transmem-  
brane segments. In summary, the skilled in this field can select the most appropriate  
method to cleave the proteins in the sample depending on factors such as the source  
30 of the sample, the purpose of the labelling etc. The digested proteins obtained ac-

According to the present invention are much easier to handle since physicochemically they are much simpler. Thus, an essential advantage with the present invention is that the separation of peptides obtained according to the invention can be selected to pick out virtually any one or ones of those present in the original sample as proteins, since the present digestion will be essentially total. Accordingly, in the step of separation and the subsequent labelling, any one of all possible peptides (fragments of proteins) can be treated, even cysteine-containing peptides, as will be discussed in more detail below. This should be compared to the prior art methods, wherein proteins can be hidden or concealed due e.g. to self-aggregation. Prior methods required the separation of intact proteins and could not deal with peptide digests without losing the quantitation aspect. The present method of cleavage provides homogeneous peptides which can be separated without the problems associated with proteins have multiple domains (hydrophobic and hydrophilic) which cause them to run at multiple positions. The present digestion method also allows the analysis of proteins that are otherwise completely insoluble or are parts of large complexes which cannot be easily separated, especially cytoskeletal aggregates or proteoglycans.

The next step of the method (step (f)) is to separate and analyse the target biomolecule with its bound mass marker part. Normally, this is performed by coupling an initial multidimensional HPLC to a mass spectrometer (MS). In one embodiment of the present method, the separation is by multi-dimensional chromatography. In another embodiment of the present method, standard reverse phase HPLC is used to separate the majority of the peptides. In a specific embodiment which is efficient if it is desired to get the most hydrophobic peptides, a hydrophilic interaction chromatography (HILIC) approach is used. Alternatively, a first dimension separation can be carried out by ion exchange in the presence of a detergent such as octylglucoside as demonstrated previously (James P, Inui M, Tada M, Chiesi M, Carafoli E. The nature and site of phospholamban regulation of the  $Ca^{2+}$  pump of sarcoplasmic reticulum. *Nature*. 1989 Nov 2;342 (6245):90-2; James, P., Quadroni, M, Carafoli, E., and Gomet, G. (1993) *Biochem.Biophys.Res.Comm.* 195, 58-64. Protein identi-

fication by mass profile fingerprinting). The detergent is then easily removed prior to RP-HPLC-MS analysis by using a normal phase precolumn.

Moreover, in a preferred embodiment of the invention, the mass marker part has the ability to fragment during the analysis step. For example, the mass marker part is thioethyl-pyridine. Hereby, a unique mass marker is achieved, which may easily be detected by mass spectrometry. In a preferred embodiment, the MS is in a parent ion scanning mode (Anal Chem 1996 Feb 1;68(3):527-33. Parent ion scans of unseparated peptide mixtures. Wilm M, Neubauer G, Mann M. and Carr et al. 1993, Anal Chem 1993 Apr 1;65(7):877-84 Collisional fragmentation of glycopeptides by electrospray ionization LC/MS and LC/MS/MS: methods for selective detection of glycopeptides in protein digests. Huddleston MJ, Bean MF, Carr SA) (also described in the example section), wherein target biomolecules comprising the thioethyl-pyridine mass marker easily are detected at 106 m/z. Furthermore, in a preferred embodiment the MS operates in a data-dependent mode, thereby switching from parent ion to daughter ion scanning mode when a target biomolecule containing the marker is detected.

In yet another embodiment, the present method comprises the method described above, which further comprises the step of identifying the amino acid sequence of at least one of the labelled peptides.

In one embodiment, amino acid sequence identification step is by mass spectral analysis using an ion trap spectrometer or a quadrupole time of flight (TOF) instrument. However, as is realised by the skilled in this field, any MS instrument capable of carrying out and measuring peptide fragmentation spectra can be used to this end.

Moreover, the amino acid identification may be followed by a data base search, in order to find homologues, or other relevant information, to the identified sequence. This may be done in order to assign a probable function for the identified sequence.

In yet another embodiment, the linker molecule may comprise a fluorescent protein tag, in order to make it possible to determine its location in the cell, to which it is introduced. Furthermore, the linker molecule may comprise a signal tag, directing it to a specific location or compartment of a cell.

In another aspect, the invention relates to a linker molecule, which is especially suitable for use in the method of the invention for cross-linking the biomolecule of interest and the target biomolecule. One can envision a wide range of possible crosslinkers that could be useful. Figure 1 shows the principal functional parts of such a molecule. Each position can be tailored to meet a variety of needs; the chemical attachment group could be an N-hydroxysuccinimide moiety for modification of lysine residues or an N-maleimide for cysteine labelling. The cleavable group could be a geminal diol for cleavage by oxidising agents or an ester linkage for base cleavage. Similarly the photoactivatable group could be an azide for rapid labelling or a benzophenone for high efficiency crosslinking. However, the mass transfer marker that will be used in all cases however will preferably be thioethylpyridine. The thioether bond is chemically extremely stable however it fragments readily under standard low energy MS/MS conditions in a triple quadrupole mass spectrometer. The group leaves as a positively charged ion with  $m/z$  of 106. This mass does not correspond to any standard fragment found during low energy fragmentation of peptides and thus provides a unique marker or tag for the peptide to which it is attached. In one preferred embodiment, the linker molecule is 2-benzophenon-4-yl-carbonylamino-4, 5-dihydroxy-6-(N-succinimidyl)-1-(4-pyridylethylthio)-3-n-hexanone (figure 2). However, many variants of this linker are possible. It should comprise the attachment part, the cleavable part, the label part and the photoactivatable part, but they should mostly be seen as functional parts, and must not necessarily be structurally distinguished from each other. The core part of the linker molecule is its ability to render a unique mass marker in the gas phase,

making it suitable for parent ion scanning, which feature is a result of the thioether bridge.

5 The main advantage of this approach compared to standard cross-linking methods using radioactive transfer markers such as the Denny-Jaffe reagent (Denny, J. B. and G. Blobel (1984). "125I-labeled crosslinking reagent that is hydrophilic, photoactivatable, and cleavable through an azo-linkage." Proc Natl Acad Sci U S A 81(17): 5286-90) is that the crosslinked peptide is unequivocally identified during parent ion scanning. Radioactive markers have the problem that the peak of radioactivity occurs in an HPLC fraction together with many other peptides and so multidimensional chromatography is necessary. Also the detection of the cross-linked product and the identification by sequencing occur concurrently.

10 In yet another aspect, the invention relates to a kit for use in the method of identifying an interacting target biomolecule to a biomolecule of interest, such as the method according to the present invention, comprising in separate compartments at least one linker molecule, and optionally the biomolecule of interest. Furthermore, the kit may comprise necessary reagents for the different steps of the method of the invention, as discussed above or in the example section. The kit comprises amounts of the reagents, which is sufficient for performing the method of the invention.

15 In one embodiment, the present kit comprises a biomolecule of interest in a suitable buffer, a linker molecule as described above, and a cleaving agent that can cleave a part of the linker under appropriate conditions, each component being present in a separate compartment. In one embodiment, the linker comprises a part that can be photo-activated to enable it to bind to a suitable target, as described above. In an alternative embodiment, said part of the linker that can be activated by chemical means, in which case the kit also comprises a suitable substance for providing such activation. In an advantageous embodiment, the present kit comprises an interacting



biomolecule bound to a linker, and optionally a chemical compound capable of activating a part of the linker to enable binding thereof to a target biomolecule.

5 In still another aspect, the invention relates to the use of a linker molecule as described above, for labelling the target biomolecule in the method of the invention.

#### Detailed description of the drawings

10 Figure 1 shows the general form of cross-linker molecule of the invention comprising chemical attachment group, cleavable linker, mass marker and photoactivatable group.

Figure 2 shows the chemical structure of a specific linker of the invention, namely 2-benzophenon-4-yl-carbonylamino-4, 5-dihydroxy-6-(N-succinimidyl)-1-(4-pyridylethylthio)-3-n-hexanone.

15 Figure 3 is a schematic outline of the principle of the mass marker transfer method of the invention including the steps of photolysis and chemical cleavage.

Figure 4 shows the parent ion scanning principle. Capillary HPLC, electrospray source, a tube with collision gas and detector are shown.

Figure 5 shows a daughter ion spectrum and HPLC UV vs. RIC trace, with relative ion count / relative UV absorption on the Y-axis and time on the X-axis.

20 Figure 6 is a photo of a diagonal gel electrophoresis run according to conventional procedure.

25 The invention will now be described with the following examples, which are only intended to be of exemplifying character, and therefore not limiting the scope of the invention in any way.

#### Examples

Example 1 – the principle of the method

To illustrate, the principle of the method is shown in Figure 3. The linker is attached to lysine residues on the bait protein. The protein is then introduced to a perforated cell or a cell extract and allowed to equilibrate before photolysis. After crosslinking the proteins are cleaved by oxidation and the mixture is first digested with cyanogen bromide and then by trypsin.

The complex peptide mixture is then analysed by multi-dimensional HPLC interfaced by electrospray ionisation to a mass spectrometer operating in parent ion scanning mode as shown diagrammatically in Figure 4. By operating the mass spectrometer in parent ion scanning mode, only those peptides that give rise to an intense ion at 106 m/z will be detected. The mass spectrometer can be programmed to operate in a data-dependant mode, switching from parent ion to daughter ion scanning mode once a peptide containing the marker is detected. Figure 5 shows a preliminary experiment that has been carried out to validate the general principle of the approach. A synthetic Calmodulin-binding peptide was modified with the crosslinker and photolysed in the presence of calcium and Calmodulin. The mixture was then digested with cyanogen bromide followed by trypsin and the peptides separated by HPLC. The UV trace in Figure 5 shows that the expected number of peptides are generated whereas the parent ion total ion current trace shows that only one peptide has been labelled by the mass marker transfer method.

Initially the inventors will synthesis again the molecule shown in Figure 2 and later they will extend this to a range of photoactivatable probes specifically tailored to certain types of problem (such as nucleotide-protein crosslinking or protein-carbohydrate for example).

Having synthesised the crosslinker molecule of Figure 2 (2-benzophenon-4-yl-carbonylamino-4, 5-dihydroxy-6-(N-succinimidyl)-1-(4-pyridylethylthio)-3-n-hexanone) it is tested using the Calmodulin system mentioned briefly above. Cal-

modulin is an 18 kDa calcium binding protein involved in calcium signal transduction in many cells. Upon binding calcium it undergoes a conformational change allowing it to bind a specific domain on its target proteins. The structure of Calmodulin alone and as a complex with several of its targets has been elucidated both by X-ray crystallography and NMR and hence will allow the inventors to validate the results they obtain from the cross-linking experiments. Calmodulin-binding domains from four different proteins have been synthesised.

#### Example 2 - Site specific introduction of probes into proteins

In order for the method to be of general use, one must be able to locate the crosslinker on the 'bait protein' at specific locations, especially if a protein interacts with more than one target. The inventors use a cell-free translation system that is commercially available, the Roche rapid translation system (RTS). The N-maleimide derivative of Figure 2 is synthesised and attached to cysteine. This in turn can be coupled to a tRNA with a defined codon specificity as described by Josef Brunner's group and more recently that of Peter Schultz. Site-specific incorporation of the crosslinker is rapidly achieved and commonly 100 µg quantities can be prepared overnight. The protein carries two affinity tags and can be rapidly purified. The protein must then be introduced into the cells of interest by either active uptake or by permeabilising the cells temporarily by digitonin. Alternatively the experiment may be carried out in cell extracts. Once the cDNA encoding the protein is correctly engineered into the carrier plasmid, one can rapidly produce mutants by PCR with the codon for the modified tRNA. Thus tens of proteins modified at different positions can be produced within a week once the system is set-up.

#### Example 3 - Methods for the analysis of large complexes

If a complex is very large another approach must be taken for the introduction of crosslinkers into the 'bait proteins'. The inventors introduce crosslinkers in a random fashion by chemical means. A very gentle method of modification for crosslinking was introduced by the group of Traut to map protein-protein interac-

tions in the ribosome. Iminothiolane, a reagent that reacts with lysine residues to give a free sulphydryl group in their place, was used to modify the intact complex under mild conditions. Oxygen was then bubbled into the solution causing neighbouring sulphydryl groups to crosslink to form disulphide bridges. The complex was then separated by diagonal gel electrophoresis, in which the first dimension is non-reducing SDS PAGE and the second is done under reducing conditions. Non crosslinked proteins appear along the diagonal axis at a position proportional to their mass whereas crosslinked proteins appear as off diagonal vertically separated pairs as shown in Figure 6. This method can be modified slightly to incorporate a mass marker introduction step between the first and second dimension. Thus all interacting pairs appearing off-diagonal can be rapidly identified by protein fragment fingerprinting (James, P., Quadroni, M., Carafoli, E., and Gonnet, G. (1993) *Biochem.Biophys.Res.Comm.* 195(1), 58-64. Protein identification by mass profile fingerprinting.) and their sites of interaction can be analysed simultaneously by the parent ion scanning method outlined in Figures 4 and 5.

#### Example 4 - High throughput interaction domain mapping

An approach to mapping domain interactions between proteins can be taken which is similar to that used for mapping epitopes (Houghten, R. A. (1985). "General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids." *Proc Natl Acad Sci U S A* 82(15): 5131-5.). The inventors synthesise a series of 20mer peptides which cover the entire sequence of a protein with 10 amino acid overlaps (i.e. 100 peptides are needed for a 100 kDa protein). Each of the peptides will have a crosslinker at its N-terminal and a long cleaveable spacer arm at its C-terminal separating it from the supporting resin. The synthesis is carried out by a standard multiparallel robotic system (e.g. that of Advanced ChemTech amongst many others) in a 96 well plate format. The known target protein, which has been labelled with a fluorescent group, is then added in the appropriate buffer to the wells and allowed to equilibrate. The wells are then washed under progressively more stringent condi-

tions and the fluorescence in each well determined after each round. Finally, the better binding peptides are then re-equilibrated with target protein and photolysed. The binding position of each peptide on the target is then determined and a domain interaction map is constructed. The procedure is then reversed and the bait protein is fluorescently labelled and used to screen the peptides from the target and the binding results are correlated with the first map to exclude non-specific interactions.

5

CLAIMS

1. A method for identifying an interacting target biomolecule to a biomolecule of interest comprising the steps of:
  - (a) providing a biomolecule of interest having specificity for the target;
  - 5 (b) binding the biomolecule of interest to at least one type of linker molecule, the linker molecule comprising at least one attachment part for binding to the biomolecule of interest, one cleavable part, one mass marker part and one photoactivatable part, for binding to the target;
  - (c) contacting the biomolecule of interest with a cell or a cell extract;
  - 10 (d) exposing the cell to photolysis, whereby the photoactivatable part binds to the target;
  - (e) cleaving the linker molecule, thereby leaving the photoactivatable part and the mass marker part bound to the target;
  - (f) analysing the product of step (e), thereby detecting the mass marker part, thus
  - 15 identifying the interacting target biomolecule to the biomolecule of interest.
2. A method according to claim 1, wherein the biomolecule of interest is a protein or a peptide.
3. A method according to claim 1, wherein the target biomolecule is a protein or a peptide.
- 20 4. A method according to any one of the preceding claims, wherein the affinity of the biomolecule of interest for the target biomolecule is in the interval of 10 mM to 0.1 pM.
5. A method according to any one of the preceding claims, wherein the attachment part of the linker molecule is designed to bind to a specific amino acid residue of
- 25 the biomolecule of interest.
6. A method according to any one of the preceding claims, wherein the cleavable part of the linker molecule is cleaved by chemical means.
7. A method according to claim 6, wherein the cleavable part is cleaved by an oxidising agent or by a base agent.

8. A method according to any one of the preceding claims, wherein the mass marker part has the ability to fragment during the analysis step.
9. A method according to any one of the preceding claims, wherein at least two different linker molecules are used.
- 5 10. A method according to any one of the preceding claims, wherein the linker molecule is 2-benzophenon-4-yl-carbonylamino-4, 5-dihydroxy-6-(N-succinimidyl)-1-(4-pyridylethylthio)-3-n-hexanone.
11. A method according to any one of the preceding claims, wherein the linker molecule further comprises a fluorescent protein tag.
- 10 12. A method according to any one of the preceding claims, wherein the linker molecule comprises a tag directing it to a subcellular location.
13. A method according to any one of the preceding claims, wherein the cell of step (c) is perforated, in the form of a cell extract or in a cell-free translation system.
14. A method according to any one of the preceding claims, wherein the photolysis  
15 of step (d) is performed by exposing the cell to UV-light.
15. A method according to step 14, wherein the photolysis is repeated at least once.
16. A method according to any one of the preceding claims, wherein the product of step (d) is chemically and/or enzymatically digested.
17. A method according to claim 16, wherein the digestion is performed by cyano-  
20 gen bromide and/or trypsin.
18. A method according to any one of the preceding claims, wherein step (f) is multidimensional HPLC coupled to a mass spectrometer (MS).
19. A method according to claim 18, wherein the MS is in a parent ion scanning mode.
- 25 20. A method according to claim 19, wherein the molecules comprising the marker is detected at 106 m/z.
21. A method according to claim 20, wherein the MS operates in a data-dependent mode, thereby switching from parent ion to daughter ion scanning mode when a peptide containing the marker is detected.

22. A linker molecule, for use in the method according to claim 1-21, for labelling a specific target biomolecule, comprising at least one attachment part for binding to the biomolecule of interest, one cleavable part, one mass marker part and one photoactivatable part, for binding to the target.
- 5 23. A linker molecule according to claim 22, wherein the attachment part of the linker molecule is a N-hydroxysuccinimide moiety or a N-maleimide.
24. A linker molecule according to claim 22 or 23, wherein the cleavable part is a geminal diol or an ester linkage.
- 10 25. A linker molecule according to any one of claims 22 to 24, wherein the photoactivatable part is an azide or a benzophenone.
26. A linker molecule according to any one of claims 22 to 25, wherein the mass marker part is thioethylpyridine.
- 15 27. A linker molecule according to any one of claims 22 to 26, wherein the linker molecule is 2-benzophenon-4-yl-carbonylamino-4, 5-dihydroxy-6-(N-succinimidyl)-1-(4-pyridylethylthio)-3-n-hexanone.
28. Use of the linker molecule according to claim 22-27 for labelling a specific target biomolecule for subsequent MS parent ion scanning.
- 20 29. A kit for use in the method according to claim 1-21 comprising at least one linker molecule according to claim 22-27, optionally together with a biomolecule of interest in separate compartments.



ABSTRACT

The invention relates to a method for monitoring interactions to a target biomolecule comprising the steps of: providing a biomolecule of interest having specificity for the target biomolecule; binding the biomolecule of interest to at least one type of linker molecule, the linker molecule comprising a unique mass marker part; introducing the biomolecule of interest to a cell; binding the linker to the target biomolecule; cleaving the linker molecule, thereby leaving the photoactivatable part and the mass marker part bound to the target; analysing the target biomolecule, thereby detecting the unique mass marker part. Preferably, the detection is carried out by MS in a parent ion scanning mode, thereby allowing the interaction between the biomolecule of interest (or bait) and the target biomolecule to be studied. Moreover, the invention relates to a unique linker molecule, as well as a kit for use in the method.

1/6




Fig. 1

2/6




Fig. 2

3/6




Fig.3

4/6




Fig. 4

5/6




Fig. 5

6/6




Fig. 6

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**